Why Intercept Pharmaceuticals Stock Caught Fire in April
Intercept Pharmaceuticals (NASDAQ: ICPT), a mid-cap liver disease specialist, saw its shares rise by a healthy 40.3% over the course of April, according to data from S&P Global Market Intelligence. Most impressively, the biotech's shares even outperformed the broader iShares Nasdaq Biotechnology ETF in April, which gained a respectable 19.5% last month.
Why did investors flock to this name in April? Intercept's shares seemed to take flight for two reasons.
Image Source: Getty Images.
Source Fool.com
